Abstract：
The increased availability of recombinant human growth hormone (rhGH), albeit at a relatively high cost, has increased a demand for treatment of children and adolescents of normal height to increase their adult stature. There are no scientific reports on the efficacy and safety of rhGH therapy in this condition, therefore, the authors comment on the possible causes and consequences based on their personal opinion and experience. As in gigantism, when GH action and end-organ are normal, enough GH is expected to result in increased growth velocity. Short-term adverse effects related to rhGH therapy for approved indications of short stature in children have been very rare. Data on long-term adverse effects are still scarce. A small increase in height might be statistically significant but not functionally or socially relevant. Considering that an increase in height represents more a desire than a need, physicians should emphasize the normality and qualities of these children, discuss with families\' alternatives, such as counseling, and refrain from supporting the concept that taller is better.
摘要：
重组人生长激素（rhGH）的可用性增加，尽管成本相对较高，增加了对正常身高的儿童和青少年的治疗需求，以增加他们的成人身材。在这种情况下，没有关于rhGH治疗的有效性和安全性的科学报告，因此,作者根据个人意见和经验对可能的原因和后果进行了评论。就像在巨人主义中一样，当GH作用和终末器官正常时，足够的GH有望导致生长速度增加。与rhGH治疗有关的短期不良反应非常罕见。关于长期不利影响的数据仍然很少。身高的小幅增加可能具有统计学意义，但与功能或社会无关。考虑到身高的增加代表了更多的愿望而不是需要，医生应该强调这些孩子的正常和素质，与家庭讨论替代方案，比如咨询,并避免支持高者更好的概念。
